Entecavir-induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide

I Vern Lim; Nurgül Özgür Yurttaş; Mesut Ayer; Şule Poturoğlu; Erdem Kınacı; İlgin Özden

doi:10.1002/ccr3.7741

Entecavir-induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide

Clin Case Rep. 2023 Aug 11;11(8):e7741. doi: 10.1002/ccr3.7741. eCollection 2023 Aug.

Authors

I Vern Lim¹, Nurgül Özgür Yurttaş², Mesut Ayer², Şule Poturoğlu³, Erdem Kınacı¹, İlgin Özden¹

Affiliations

¹ Department of General Surgery, Liver Transplantation & Hepatopancreatobiliary Surgery Unit Başakşehir Çam & Sakura City Hospital Istanbul Turkey.
² Department of Internal Medicine, Division of Hematology Başakşehir Çam & Sakura City Hospital Istanbul Turkey.
³ Department of Internal Medicine, Division of Gastroenterology Başakşehir Çam & Sakura City Hospital Istanbul Turkey.

Abstract

At 22 weeks post-transplantation for HBV-related cirrhosis, an adult woman developed neutropenia which was aggravated by COVID-19 (ANC 0.4 × 10⁹/L). Covid resolution and all "conventional" modifications were ineffective. Success within 2 weeks was achieved by switching entecavir to tenofovir alafenamide. A step-by-step judicious approach to post-transplant neutropenia is vital.

Keywords: COVID‐19; entecavir; liver transplantation; neutropenia; tenofovir alafenamide.

Publication types

Case Reports